Moving Toward Biomarker-Driven Care in Bladder Cancer
Project Oncology®Moving Toward Biomarker-Driven Care in Bladder Cancer
Benjamin Garmezy, MD
Optimizing Patient Selection for Perioperative Therapy in Bladder Cancer
Project Oncology®Optimizing Patient Selection for Perioperative Therapy in Bladder Cancer
Benjamin Garmezy, MD
What's Next for Urothelial Cancer Treatment?
Project Oncology®What's Next for Urothelial Cancer Treatment?
Benjamin Garmezy, MD
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Project Oncology®Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Project Oncology®What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Petros Grivas, MD, PhD
Supporting Patients Throughout Urothelial Carcinoma Treatment
Project Oncology®Supporting Patients Throughout Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
- advertisement
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
CME/CEShifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
David Staskin, MD
Matt T. Rosenberg, MD
Kennedy Koebbe, MSN, RN
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
CME/CEExpert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
Patient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
CME/CE Broadcast ReplayPatient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
Mary-Ellen Taplin, MD
Ignacio Duran, MD
Wenxin Xu, MD
Sandy Srinivas, MD
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD
Wenxin Xu, MD
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Ignacio Duran, MD
Sandy Srinivas, MD
- advertisement